000132593 001__ 132593
000132593 005__ 20240228135110.0
000132593 0247_ $$2doi$$a10.1200/JCO.2013.50.9539
000132593 0247_ $$2pmid$$apmid:24493713
000132593 0247_ $$2pmc$$apmc:PMC3948094
000132593 0247_ $$2ISSN$$a0732-183X
000132593 0247_ $$2ISSN$$a1527-7755
000132593 0247_ $$2altmetric$$aaltmetric:2119027
000132593 037__ $$aDKFZ-2018-00257
000132593 041__ $$aeng
000132593 082__ $$a050
000132593 1001_ $$aShih, David J H$$b0
000132593 245__ $$aCytogenetic prognostication within medulloblastoma subgroups.g
000132593 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2014
000132593 3367_ $$2DRIVER$$aarticle
000132593 3367_ $$2DataCite$$aOutput Types/Journal article
000132593 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521638142_923
000132593 3367_ $$2BibTeX$$aARTICLE
000132593 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132593 3367_ $$00$$2EndNote$$aJournal Article
000132593 520__ $$aMedulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication.Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models.Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas.Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials.
000132593 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000132593 588__ $$aDataset connected to CrossRef, PubMed,
000132593 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000132593 650_7 $$2NLM Chemicals$$aGLI2 protein, human
000132593 650_7 $$2NLM Chemicals$$aHedgehog Proteins
000132593 650_7 $$2NLM Chemicals$$aKruppel-Like Transcription Factors
000132593 650_7 $$2NLM Chemicals$$aMYC protein, human
000132593 650_7 $$2NLM Chemicals$$aNuclear Proteins
000132593 650_7 $$2NLM Chemicals$$aProto-Oncogene Proteins c-myc
000132593 650_7 $$2NLM Chemicals$$aSHH protein, human
000132593 650_7 $$2NLM Chemicals$$aWnt Proteins
000132593 650_7 $$2NLM Chemicals$$aZinc Finger Protein Gli2
000132593 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b1
000132593 7001_ $$aRemke, Marc$$b2
000132593 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b3$$udkfz
000132593 7001_ $$aRamaswamy, Vijay$$b4
000132593 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b5$$udkfz
000132593 7001_ $$aLuu, Betty$$b6
000132593 7001_ $$aYao, Yuan$$b7
000132593 7001_ $$aWang, Xin$$b8
000132593 7001_ $$aDubuc, Adrian M$$b9
000132593 7001_ $$aGarzia, Livia$$b10
000132593 7001_ $$aPeacock, John$$b11
000132593 7001_ $$aMack, Stephen C$$b12
000132593 7001_ $$aWu, Xiaochong$$b13
000132593 7001_ $$aRolider, Adi$$b14
000132593 7001_ $$aMorrissy, A Sorana$$b15
000132593 7001_ $$aCavalli, Florence M G$$b16
000132593 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b17$$udkfz
000132593 7001_ $$aZitterbart, Karel$$b18
000132593 7001_ $$aFaria, Claudia C$$b19
000132593 7001_ $$aSchüller, Ulrich$$b20
000132593 7001_ $$aKren, Leos$$b21
000132593 7001_ $$aKumabe, Toshihiro$$b22
000132593 7001_ $$aTominaga, Teiji$$b23
000132593 7001_ $$aShin Ra, Young$$b24
000132593 7001_ $$aGarami, Miklós$$b25
000132593 7001_ $$aHauser, Peter$$b26
000132593 7001_ $$aChan, Jennifer A$$b27
000132593 7001_ $$aRobinson, Shenandoah$$b28
000132593 7001_ $$aBognár, László$$b29
000132593 7001_ $$aKlekner, Almos$$b30
000132593 7001_ $$aSaad, Ali G$$b31
000132593 7001_ $$aLiau, Linda M$$b32
000132593 7001_ $$aAlbrecht, Steffen$$b33
000132593 7001_ $$aFontebasso, Adam$$b34
000132593 7001_ $$aCinalli, Giuseppe$$b35
000132593 7001_ $$aDe Antonellis, Pasqualino$$b36
000132593 7001_ $$aZollo, Massimo$$b37
000132593 7001_ $$aCooper, Michael K$$b38
000132593 7001_ $$aThompson, Reid C$$b39
000132593 7001_ $$aBailey, Simon$$b40
000132593 7001_ $$aLindsey, Janet C$$b41
000132593 7001_ $$aDi Rocco, Concezio$$b42
000132593 7001_ $$aMassimi, Luca$$b43
000132593 7001_ $$aMichiels, Erna M C$$b44
000132593 7001_ $$aScherer, Stephen W$$b45
000132593 7001_ $$aPhillips, Joanna J$$b46
000132593 7001_ $$aGupta, Nalin$$b47
000132593 7001_ $$aFan, Xing$$b48
000132593 7001_ $$aMuraszko, Karin M$$b49
000132593 7001_ $$aVibhakar, Rajeev$$b50
000132593 7001_ $$aEberhart, Charles G$$b51
000132593 7001_ $$aFouladi, Maryam$$b52
000132593 7001_ $$aLach, Boleslaw$$b53
000132593 7001_ $$aJung, Shin$$b54
000132593 7001_ $$aWechsler-Reya, Robert J$$b55
000132593 7001_ $$aFèvre-Montange, Michelle$$b56
000132593 7001_ $$aJouvet, Anne$$b57
000132593 7001_ $$aJabado, Nada$$b58
000132593 7001_ $$aPollack, Ian F$$b59
000132593 7001_ $$aWeiss, William A$$b60
000132593 7001_ $$aLee, Ji-Yeoun$$b61
000132593 7001_ $$aCho, Byung-Kyu$$b62
000132593 7001_ $$aKim, Seung-Ki$$b63
000132593 7001_ $$aWang, Kyu-Chang$$b64
000132593 7001_ $$aLeonard, Jeffrey R$$b65
000132593 7001_ $$aRubin, Joshua B$$b66
000132593 7001_ $$ade Torres, Carmen$$b67
000132593 7001_ $$aLavarino, Cinzia$$b68
000132593 7001_ $$aMora, Jaume$$b69
000132593 7001_ $$aCho, Yoon-Jae$$b70
000132593 7001_ $$aTabori, Uri$$b71
000132593 7001_ $$aOlson, James M$$b72
000132593 7001_ $$aGajjar, Amar$$b73
000132593 7001_ $$aPacker, Roger J$$b74
000132593 7001_ $$aRutkowski, Stefan$$b75
000132593 7001_ $$aPomeroy, Scott L$$b76
000132593 7001_ $$aFrench, Pim J$$b77
000132593 7001_ $$aKloosterhof, Nanne K$$b78
000132593 7001_ $$aKros, Johan M$$b79
000132593 7001_ $$aVan Meir, Erwin G$$b80
000132593 7001_ $$aClifford, Steven C$$b81
000132593 7001_ $$aBourdeaut, Franck$$b82
000132593 7001_ $$aDelattre, Olivier$$b83
000132593 7001_ $$aDoz, François F$$b84
000132593 7001_ $$aHawkins, Cynthia E$$b85
000132593 7001_ $$aMalkin, David$$b86
000132593 7001_ $$aGrajkowska, Wieslawa A$$b87
000132593 7001_ $$aPerek-Polnik, Marta$$b88
000132593 7001_ $$aBouffet, Eric$$b89
000132593 7001_ $$aRutka, James T$$b90
000132593 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b91$$udkfz
000132593 7001_ $$aTaylor, Michael D$$b92
000132593 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.2013.50.9539$$gVol. 32, no. 9, p. 886 - 896$$n9$$p886 - 896$$tJournal of clinical oncology$$v32$$x1527-7755$$y2014
000132593 909CO $$ooai:inrepo02.dkfz.de:132593$$pVDB
000132593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000132593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b91$$kDKFZ
000132593 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000132593 9141_ $$y2014
000132593 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132593 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2015
000132593 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132593 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132593 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132593 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132593 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132593 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132593 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132593 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132593 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132593 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bJ CLIN ONCOL : 2015
000132593 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000132593 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x1
000132593 980__ $$ajournal
000132593 980__ $$aVDB
000132593 980__ $$aI:(DE-He78)G380-20160331
000132593 980__ $$aI:(DE-He78)B062-20160331
000132593 980__ $$aUNRESTRICTED